Drug Interaction Risk Assessment: Fluvoxamine with Melatonin and Diazepam
Fluvoxamine 100 mg + Diazepam 5 mg: HIGH RISK - Generally Not Advisable
The co-administration of fluvoxamine and diazepam is generally not advisable and should be avoided. 1
Mechanism and Severity
Fluvoxamine dramatically impairs diazepam metabolism through potent CYP450 enzyme inhibition, leading to dangerous drug accumulation:
- Diazepam clearance reduced by 65% in healthy volunteers taking fluvoxamine 150 mg/day 1
- N-desmethyldiazepam (active metabolite) clearance reduced to unmeasurable levels over a 2-week study period 1
- Diazepam half-life prolonged from 51 to 118 hours (more than doubled) with fluvoxamine co-administration 2
- Strong likelihood of substantial accumulation of both parent drug and active metabolite during chronic co-administration 1
Clinical Consequences
The magnitude of this interaction creates serious safety concerns:
- Progressive accumulation of diazepam and its active metabolite with repeated dosing
- Enhanced CNS depression (excessive sedation, respiratory depression)
- Impaired psychomotor performance and memory 1
- Risk increases with higher fluvoxamine doses (your 100 mg dose falls in the concerning range)
Critical Caveat
The FDA label explicitly states: "diazepam and fluvoxamine should not ordinarily be co-administered." 1 The study data likely underestimate the degree of accumulation with repeated diazepam administration, and effects may be more pronounced at fluvoxamine doses of 100-300 mg due to non-linear pharmacokinetics 1.
Fluvoxamine 100 mg + Melatonin 5 mg: MODERATE-HIGH RISK - Requires Dose Adjustment
Fluvoxamine dramatically increases melatonin exposure (17-fold increase in drug levels), requiring substantial melatonin dose reduction if co-administered. 3
Mechanism and Severity
Fluvoxamine is an extremely potent inhibitor of melatonin metabolism:
- 17-fold increase in melatonin AUC (area under the curve) 3
- 12-fold increase in peak melatonin concentrations (Cmax) 3
- Melatonin is almost exclusively metabolized by CYP1A2, which fluvoxamine potently inhibits (Ki = 0.02 μM for 6-hydroxymelatonin formation) 4
- Correlation exists between fluvoxamine and melatonin serum levels (r = 0.63) 3
Clinical Implications
This interaction is pharmacologically significant but potentially manageable:
- The interaction occurs through inhibition of melatonin elimination, not increased production 3
- Effects are dose-dependent and related to fluvoxamine concentrations
- Your 5 mg melatonin dose is already at the upper end of typical dosing - with fluvoxamine, this could result in exposure equivalent to 60-85 mg melatonin
- Excessive melatonin can cause daytime sedation, dizziness, headache, and disrupted sleep architecture
Management Strategy
If this combination is necessary:
- Reduce melatonin dose to 0.3-0.5 mg (roughly 1/10th to 1/15th of current dose) when starting fluvoxamine
- Monitor for excessive sedation, morning grogginess, or paradoxical sleep disruption
- Consider that fluvoxamine itself elevates endogenous melatonin levels 5, potentially providing some benefit without exogenous supplementation
- CYP2D6 poor metabolizers show even more pronounced interactions 3
Important Context
Unlike diazepam, this interaction has been studied specifically and can be managed with appropriate dose reduction. However, the magnitude of the pharmacokinetic change is substantial and clinically relevant.
Summary Algorithm
For Diazepam + Fluvoxamine:
- Avoid this combination - seek alternative anxiolytic (lorazepam, oxazepam, or temazepam are safer as they undergo glucuronidation, not oxidative metabolism) 6, 1
For Melatonin + Fluvoxamine:
- Reduce melatonin to 0.3-0.5 mg if combination is necessary
- Monitor closely for excessive sedation
- Consider discontinuing melatonin entirely, as fluvoxamine may provide adequate melatonergic effects through endogenous elevation 5